Biomimetic implant for orthopedic surgery

脊柱植入物是一项重要的全球业务，2009年的收入为65亿美元。虽然目前的合成技术已经证明了临床上的成功，但今天的现实是，这些植入物远远不如天然骨。最近，对与自体骨移植性能相当或更好的人工骨的研究有所加强，但还没有产品达到自体骨移植(即从患者的髂骨获取的骨)的突出地位，因此自体骨移植仍然主导着市场。 该项目的目标是开发一种工程生物材料，模拟自然骨的所有有益特性，并避免痛苦的骨采集过程。这项技术将在一系列新的脊柱产品中实施--这是工业赞助商辛烷矫形生物制品公司的核心专业领域。拟议的动物工作是指定和验证材料性能。 这项拟议的技术是独一无二的，因为天然骨的四个关键属性将首次在完全合成的生物材料中复制。这一成就将导致第一种人造骨生物材料，其性能与天然骨的黄金标准没有区别，同时避免了与自然来源组织相关的风险。 最终的结果将是一种合成的、可定制的仿生植入物，其性能将与天然骨组织相匹配或超过天然骨组织。

Spinal implants represent a significant global business with revenues at US$6.5B (2009). While current synthetic technologies have demonstrated clinical success, today's reality is that these implants are far inferior to natural bone. Recently, the search for a synthetic bone graft that performs as well or better than autograft has intensified, but no product has yet to reach the prominence of autologous bone grafts (i.e. bone harvested from patient's iliac crest) and consequently autograft still dominates the market. The objective of this project is to develop an engineered biomaterial that emulates all the beneficial properties of natural bone and avoids the painful bone harvest procedure. The technology will be implemented in an array of new spinal products - a core area of expertise of the industrial sponsor, Octane Orthobiologics Inc. The animal work proposed is to specify and validate material performance. The proposed technology is unique in that the four key attributes of natural bone will be replicated for the first time in a fully synthetic biomaterial. This achievement will result in the first synthetic bone biomaterial that has a performance indistinguishable from the gold standard of natural bone, while simultaneously avoiding the risks associated with naturally sourced tissues. The net result will be a synthetic and customizable biomimetic implant that will match or exceed the performance of natural bone tissue.